Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1562 - Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)

Date

10 Sep 2017

Session

Poster display session

Presenters

Miguel Angel Climent Duran

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

M.A. Climent Duran1, B. Mellado2, J.M. Piulats Rodriguez3, L. Heras Lopez4, M.J. Juan1, M.I. Sáez5, O. Reig2, A. Montesa6, J.F. Suarez7, R. Hajianfar8, M.J. Ribal2, J. Rubio1, M. Castells7, R. Villatoro9, S. Sandiego1, D. Olmos Hidalgo10

Author affiliations

  • 1 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 2 Medical Oncology, Hospital Clinic, 08 - barcelona/ES
  • 3 Medical Oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 4 Medical Oncology, Hospital Sant Joan Despí Moises Broggi, Sant Joan Despí/ES
  • 5 Medical Oncology, H Universitario Virgen de la Victoria y Regional de Málaga, Malaga/ES
  • 6 Cnio-ibima Genitourinary Research Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga., Málaga/ES
  • 7 Urology, Hospital Bellvitge, Barcelona/ES
  • 8 Urology, Hospital Sant Joan Despí Moises Broggi, Sant Joan Despí/ES
  • 9 Medical Oncology, Hospital Costa del Sol, Málaga/ES
  • 10 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 028029 - Madrid/ES
More

Resources

Abstract 1562

Background

Addition of 6 cycles of docetaxel to ADT prolongs survival and is the standard treatment for mHSPC based on results of Chaarted and Stampede trials. Prognostic factors have not been clearly described for these patients. A retrospective analysis of clinical and pathological prognostic factors was performed in 76 patients from 5 academic institutions.

Methods

Retrospective analysis of all (n = 76) mHSPC from 5 Spanish Oncology Centres was performed. All patients had been treated with docetaxel + ADT as first line. Clinical and pathological variables were analyzed: age, Gleason (6-7 vs 8-10), presence of visceral metastases, number of bone metastases (0,1-4,5-20,>20), PSA value at diagnosis and previous to CT, PSA response previous to CT (>25%, 25-50%, 50-100% or no response), time from diagnosis to first docetaxel treatment (>or< 50days). Progression free (PFS) and overall survival (OS) were the endpoints analyzed by log-rank test.

Results

Median PFS was 17m and median OS has not been reached (80% of patients alive at 20 months). Median follow-up: 16.6m. Median age 64,3y (range: 46-80), median PSA at diagnosis 691ng/mL (range:15235-1), median PSA previous to CT 214ng/mL (range:5060-0), PSA responses to ADT previous to CT was 25% in 35 pts (46%), 25-50% in 14 pts (18.4%), less than 50% in 13 (17.2%), no response in 14 (18.4%), Gleason 6-7: 19 (25%), 8-10: 53 (69,7%), UK 3 (5.3%). Median time from diagnosis to docetaxel 45.3 d (range 0-167). PFS nor OS was related to age, PSA at diagnosis, PSA response prior to docetaxel or Gleason. Time from diagnosis to docetaxel (p = 0.04) (median 21 vs 15m; HR:2.2)) and Gleason (median not reached vs 15m; HR: 3.3) were statistically significant factors for PFS. Presence of visceral metastasis (p = 0.08) (20m vs median not reached;HR: 3.8) and time from diagnosis to docetaxel (p = 0.02) (median not reached vs 24m; HR:4.1) were significative factors for OS.

Conclusions

A time from diagnosis to docetaxel start longer than 50 days is associated with lower PFS and OS in m+HSPC patients treated with ADT + docetaxel. Gleason ≥ 8 score correlates with shorter PFS and the presence of visceral metastases with a lower OS.

Clinical trial identification

Legal entity responsible for the study

Dr. Miguel A. Climent Durán

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.